Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Previously Treated Patients ◽

Dose Combination ◽

Faculty Opinions recommendation of Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718170953.793488463 ◽

2013 ◽

Author(s):

Doug Dieterich ◽

Kian Bichoupan

Keyword(s):

Fixed Dose ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Previously Treated Patients ◽

Dose Combination ◽

Faculty Opinions recommendation of Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718170953.793487776 ◽

2013 ◽

Author(s):

Cihan Yurdaydin

Keyword(s):

Fixed Dose ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Previously Treated Patients ◽

Dose Combination ◽

Faculty Opinions recommendation of Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725431366.793505980 ◽

2015 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C ◽

Japanese Patients ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Treatment Naïve ◽

Dose Combination ◽

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(15)70099-x ◽

2015 ◽

Vol 15 (6) ◽

pp. 645-653 ◽

Cited By ~ 255

Author(s):

Masashi Mizokami ◽

Osamu Yokosuka ◽

Tetsuo Takehara ◽

Naoya Sakamoto ◽

Masaaki Korenaga ◽

...

Keyword(s):

Hepatitis C ◽

Japanese Patients ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Treatment Naïve ◽

Dose Combination ◽

Faculty Opinions recommendation of Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020296.793478787 ◽

2013 ◽

Author(s):

Arthur Kim

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Genotype 1 ◽

Hepatitis C Infection ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Ns3 Protease

Faculty Opinions recommendation of Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726172820.793515335 ◽

2016 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Advanced Liver Disease ◽

Phase 2 Trial

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(16)00052-9 ◽

2016 ◽

Vol 16 (6) ◽

pp. 685-697 ◽

Cited By ~ 300

Author(s):

Michael Manns ◽

Didier Samuel ◽

Edward J Gane ◽

David Mutimer ◽

Geoff McCaughan ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Advanced Liver Disease ◽

Phase 2 Trial

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(16)30408-x ◽

2017 ◽

Vol 17 (2) ◽

pp. 215-222 ◽

Cited By ~ 65

Author(s):

Katja Deterding ◽

Christoph D Spinner ◽

Eckart Schott ◽

Tania M Welzel ◽

Guido Gerken ◽

...

Keyword(s):

Hepatitis C ◽

Fixed Dose ◽

Acute Hepatitis C ◽

Phase 2 ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Study ◽

Acute Hcv ◽

Dose Combination

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

Gastroenterology ◽

10.1053/j.gastro.2016.07.039 ◽

2016 ◽

Vol 151 (5) ◽

pp. 893-901.e1 ◽

Cited By ~ 38

Author(s):

Eric Lawitz ◽

Nancy Reau ◽

Federico Hinestrosa ◽

Mordechai Rabinovitz ◽

Eugene Schiff ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

The Lancet ◽

10.1016/s0140-6736(10)60934-8 ◽

2010 ◽

Vol 376 (9742) ◽

pp. 705-716 ◽

Cited By ~ 490

Author(s):

Paul Y Kwo ◽

Eric J Lawitz ◽

Jonathan McCone ◽

Eugene R Schiff ◽

John M Vierling ◽

...

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Genotype 1 ◽

Hepatitis C Infection ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Ns3 Protease